83,780 Shares in Aurinia Pharmaceuticals Inc $AUPH Purchased by Navellier & Associates Inc.

Navellier & Associates Inc. purchased a new stake in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 83,780 shares of the biotechnology company’s stock, valued at approximately $926,000. Navellier & Associates Inc. owned 0.06% of Aurinia Pharmaceuticals at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Personalized Indexing Management LLC increased its holdings in shares of Aurinia Pharmaceuticals by 27.2% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 13,892 shares of the biotechnology company’s stock valued at $154,000 after purchasing an additional 2,973 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in Aurinia Pharmaceuticals by 32.4% during the second quarter. BNP Paribas Financial Markets now owns 13,034 shares of the biotechnology company’s stock worth $110,000 after buying an additional 3,191 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Aurinia Pharmaceuticals by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,811 shares of the biotechnology company’s stock worth $642,000 after buying an additional 3,497 shares in the last quarter. Creative Planning grew its position in Aurinia Pharmaceuticals by 21.0% during the second quarter. Creative Planning now owns 20,699 shares of the biotechnology company’s stock valued at $175,000 after buying an additional 3,594 shares during the period. Finally, Hudson Bay Capital Management LP increased its holdings in Aurinia Pharmaceuticals by 4.0% in the second quarter. Hudson Bay Capital Management LP now owns 104,000 shares of the biotechnology company’s stock valued at $881,000 after buying an additional 4,000 shares in the last quarter. Institutional investors and hedge funds own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Stock Up 0.2%

AUPH stock opened at $14.56 on Wednesday. Aurinia Pharmaceuticals Inc has a 52 week low of $6.55 and a 52 week high of $16.54. The company has a quick ratio of 5.17, a current ratio of 5.76 and a debt-to-equity ratio of 0.15. The firm has a 50-day simple moving average of $15.31 and a 200-day simple moving average of $13.60. The stock has a market capitalization of $1.92 billion, a P/E ratio of 26.00 and a beta of 1.50.

Analyst Upgrades and Downgrades

AUPH has been the topic of several recent analyst reports. Weiss Ratings reissued a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a research note on Wednesday, January 21st. Bloom Burton lowered Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, November 5th. Leerink Partners downgraded Aurinia Pharmaceuticals from an “outperform” rating to a “market perform” rating and increased their price target for the stock from $15.00 to $16.00 in a research report on Wednesday, December 3rd. Jefferies Financial Group raised Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price objective for the company from $10.00 to $21.00 in a report on Friday, November 7th. Finally, Royal Bank Of Canada restated a “sector perform” rating and issued a $15.00 price objective (up from $9.00) on shares of Aurinia Pharmaceuticals in a research report on Wednesday, November 5th. Two equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, Aurinia Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $17.25.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.